Garuda - Garba Rujukan Digital

p-Index From 2021 - 2026

2.554

P-Index

This Author published in this journals

All Journal HAYATI Journal of Biosciences Indonesian Journal of Cancer Universa Medicina Jurnal Respirologi Indonesia Jurnal Ilmu Kefarmasian Indonesia Jurnal Respirasi (JR) Sumatera Medical Journal JURNAL PENELITIAN KEPERAWATAN MEDIK Respiratory Science Cermin Dunia Kedokteran Indonesian Journal of Cancer eJournal Kedokteran Indonesia

Elisna Syahruddin

Department Of Pulmonology And Respiratory Medicine, Faculty Of Medicine, Universitas Indonesia

Author-ID : 3605425

Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Earth & Planetary Sciences Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 28 Documents Claim Missing Document

Claim Missing Document

Articles

1 2 3

Programmed Death Ligand 1 (PD-L1) Expression in Lung Adenocarcinoma Patients Rahmat Hidayat; Noni Novisari Soeroso; Elisna Syahruddin; Dian Cahyadi; Setiaputra Setiaputra
Respiratory Science Vol. 1 No. 3 (2021): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v1i3.16

Background: Programmed Death Ligand 1 (PD-L1) is a protein found in tumor cells that could inactivate T-cells. This research was done to identify the characteristics of lung adenocarcinoma patients to PD-L1 expression in Medan. Method: Descriptive research with a cross-sectional design was used and the study was done for 12 months (January – December 2018). Sample’s collection was done at RSUP (Central Public Hospital) H. Adam Malik and the samples diagnosed with lung adenocarcinoma based on histopathological subtyping were sent to the laboratory of Dharmais Jakarta Hospital where the Ventana 22C3 Immunohistochemistry Staining was done. Results: Staining was done in 52 samples at Dharmais Jakarta Hospital and only 35 samples were deemed acceptable. In this study, participants’ ages ranged from 40 to 60 years, where the majority were male patients, 31 (88.6%) and 33 patients (82.5%) were at an advanced stage (III and IV). Conclusion: The study found that the PD-L1 expression was mostly observed in male at the age range of 40 – 60 years and stage IV lung adenocarcinoma patients with Tumour Proportion Score (TPS) of 1 – 49%.

Masalah Kanker Paru pada Usia Lanjut Andika Chandra Putra; Fariz Nurwidya; Sita Andarini; Jamal Zaini; Elisna Syahruddin; Ahmad Hudoyo; Anwar Jusuf
Cermin Dunia Kedokteran Vol 42, No 11 (2015): Kanker
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v42i11.948

Kanker paru masih menjadi masalah kesehatan yang sulit diatasi bukan saja karena meningkatnya jumlah perokok di Indonesia tetapi juga disebabkan tingginya mortalitas dan morbiditas penderita. Beberapa panduan pengobatan merekomendasikan penanganan multimodalitas. Tatalaksana kanker paru cenderung tidak optimal pada usia lanjut padahal hampir separuh penderita kanker paru berusia di atas 65 tahun. Pasien kanker paru berusia lanjut sering memiliki penyakit komorbid, status tampilan buruk serta risiko toksisitas terapi tinggi. Tulisan ini merupakan tinjauan pustaka tatalaksana kanker paru pada usia lanjut.Lung cancer remains a health problem in Indonesia because of increase of young smokers and its high mortality and morbidity. There is a tendency of inadequate management of lung cancer among elderly patients despite fact that almost half of lung cancer patients aged over 65 years. Lung cancer management is still challenging and need comprehensive approach since older patients are more likely to have decreased functional reserve which limit their ability to undergo surgery or receive chemotherapy. Several guidelines recommended multimodality treatment. Ageing is also associated with increased co-morbid medical conditions that could exacerbate and influence outcome. This article will discuss treatment of lung cancer in elderlies.

Gejala Klinis Neurologis dan Gambaran CT Scan Otak Pasien Kanker Paru Karsinoma Bukan Sel Kecil Metastasis ke Otak di Rumah Sakit Persahabatan DIAN YULIANTI; ELISNA SYAHRUDDIN; AHMAD HUDOYO; AZIZA ICKSAN
Indonesian Journal of Cancer Vol 4, No 1 (2010): Jan - Mar 2010
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v4i1.78

Brain is one of the common sites of distant metastasis in patients of lung cancer, and incidens of brain metastasis in lung cancer is considered high. In Non-small Cell lung cancer guide line, brain CT done if the neurological symptom occured. Therefore analysis of diagnostic approach related to brain metastases is needed. Prospective analysis of 35 patients newly diagnosed cases of brain metastases in NSCLC. Cross sectional study with additional analysis to find relationship of clinical symptom to result of CT brain over periode July 2008-August 2009 in Persahabatan Hospital. Data were analysed as regards to the presence/absence of neurogical symtomps. Prognostic approach was applied to analyze survival rate.We found that 85,7% patients brain metastases with neurological symptomatic and 14,3% asymptomatic. Five (14,3%) patients with more than one neurologycal symptoms. Depend on stage and cell type of which 27 (77,1%) with adenocarcinoma, 21 (62,9%) with T4, 17 (48,6%) N0 and patients with soliter nodule 8 (22,9%). Theres no correlation between neurologycal symptom and brain metastases. Median survival time of lung cancer patients with brain metastases are 11 month. The majority lung cancer patients with brain metastasis have neurological symptoms. The most brain metatases found in patient with adenocarcinoma, T4 and N0. Median survival was increased in treated patients Keywords: Lung cancer, NSCLC, Brain metastases, Neurological symptoms

Ekspresi Protein Gen p53 yang Bermutasi pada Jaringan Sediaan Blok Parafin Kanker Paru Karsinoma Bukan Sel Kecil ARIF R HANAFI; ELISNA SYAHRUDDIN; AHMAD HUDOYO
Indonesian Journal of Cancer Vol 4, No 3 (2010): Jul - Sep 2010
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v4i3.101

The tumor supressor gen p53 mutation encodes a protein that inhibits programmed cell death (apoptosis). The protein is expressed in basal cells in normal human epithelium, but no data are available on the frequency or clinical importance of its expression in carcinoma. We studied p53 mutation protein expression in post surgery tissues of patients with non-small cell lung carcinoma (NSCLC) and evaluated the correlation between protein expressions with prognosis of diseases. We have performed a retrospective study using 43 parafin block samples of NSCLC patients who were underwent surgery in Persahabatan Hospital during 1997 to 2008. The p53 mutation protein expression were analyzed by immunohystochemical method using a monoclonal antibody specific for p53 mutation protein. The possibility that p53 mutation expression correlated with survival was investigated with the log-rank test Kaplan Meier. Patients characteristic we found male 25/43 (58.1%) female 18/43 (41.9%) with mean age 56.19 + 8.3 y.o and mostly age 40 to 60 y.o 33/43 (76.7%). Number of smoker patiens were 31/43 (72.1%). We also detected p53 mutation protein in 16/43 (37,2%) in NSCLC tissues. Regarding histopatology types were 9/18 (50%) in squamous-cell carcinomas and 7/25 (28%) in adenocarcinomas. The corellation between positive p53 mutation protein expressions with pathological staging was significant p 0,004, according to T status T1-T2 62,5% and T3-T4 23,8% have had positive p53 mutation protein. Favorable prognostic significance of p53 mutation in patients with NSCLC stage I II, patients in the positive p53 mutataion survived longer than those in negative with respective median survival durations 28 and 18 months p 0,019. Adenocarcinomas type with p53 mutation have had median survival 11 months compared with squamose cell carcinomas 14 months.

Radiology Appearance of Malignant Peripheral Nerve Sheath Tumor: a Case Report Aziza G Icksan; Yopi Simargi; Elisna Syahruddin; Heriawaty Hidajat
Indonesian Journal of Cancer Vol 3, No 4 (2009): Oct - Dec 2009
Publisher : National Cancer Center - Dharmais Cancer Hospital

Malignant peripheral nerve sheath tumor (MPNST) merupakan sarkoma jaringan lunak yang jarang. Tumor ini meliputi MPNST sampai 10% dari 1-2 per 100.000 populasi/tahun kasus sarkoma jaringan lunak. Makalah ini memaparkan kasus MPNST yang ditemukan di permukaan tubuh, yaitu kepala bagian frontal, temporal, parietal kanan, leher, lengan kiri, torso, dan di organ-organ dalam yaitu otak, paru-paru, hepar, ginjal kanan, intraabdomen kiri, dan tanpa terkait dengan neurofibromatosis tipe 1 (NF1) serta tanpa riwayat terapi radiasi. Pasien hanya mengeluh sakit pada benjolan di punggung. Gambaran computed tomography (CT) otak ditemukan massa jaringan lunak di subkutis frontal dan parietal, serta lesi hipodens di serebri frontal yang menyangat di perifer setelah pemberian kontras dicurigai ke arah keganasan. Pada foto toraks dan CT paru ditemukan nodul multipel. Tampak pula massa pada ginjal kanan dan massa intrabdomen kiri. Massa heterogen pada hepar lobus kiri ditemukan pada ultrasonografi abdomen. Pemeriksaan histologi memastikan diagnosis MPNST. Pasien ini direncanakan untuk perawatan paliatif.Kata kunci: Radiologi. MPNST, sarkoma

Observational Study of Paclitaxel-Carboplatin versus Pemetrexed-Carboplatin for Advanced Pulmonary Adenocarcinoma at Single-Centre in Indonesia Rianyta Rianyta; Melva Louisa; Elisna Syahruddin; Vivian Soetikno
eJournal Kedokteran Indonesia Vol 9, No. 3 - Desember 2021
Publisher : Faculty of Medicine Universitas Indonesia

Platinum-based chemotherapy regimens with two types of drugs, such as paclitaxel-carboplatin and pemetrexedcarboplatin, are first-line therapy for pulmonary adenocarcinoma patients with negative epidermal growth factor receptor (EGFR) mutation. This study aimed to determine the efficacy, toxicity, and cost profile of paclitaxel-carboplatin compared to pemetrexed-carboplatin. This is a cross-sectional study. Pulmonary adenocarcinoma negative EGFR mutation naïve patients treated with paclitaxel-carboplatin or pemetrexed-carboplatin were included. Effectiveness was assessed based on the overall response rate (ORR) according to the response evaluation criteria in solid tumours (RECIST). A pharmacoeconomic analysis is performed based on clinical outcomes consisting of effectiveness and direct medical costs. Medical records from 21 patients with paclitaxel-carboplatin and 21 patients with pemetrexedcarboplatin were successfully evaluated. The effectiveness of the two chemotherapy regimens was not significantly different (OR, 1.25; 95% confidence interval, 0.34 to 4.64; p = 0.739). Frequent haematological toxicities experienced in the two groups were grade 1-2 anaemia, neutropenia, leukopenia. Grade 3 anaemia, leukopenia, and neutropenia were more common in the paclitaxel-carboplatin group. The two groups’ nonhematological toxicities were nausea vomitus and hair loss, with peripheral neuropathy more experienced by the paclitaxel-carboplatin group. Costminimization analysis reveals that the average cost per patient with pulmonary adenocarcinoma negative EGFR mutation with paclitaxel-carboplatin regimen was cheaper IDR 10,986,257.55 or 50.25%, compared to pemetrexedcarboplatin. In conclusion, there was no significant difference in the effectiveness of the two regimens. The most common adverse effects in both regimens were haematological toxicities. The average cost per patient with a paclitaxel-carboplatin regimen was cheaper compared to pemetrexed-carboplatin.

Indonesian Society of Respirology (ISR) Consensus Statement on Lung Cancer Screening and Early Detection in Indonesia Sita Andarini; Elisna Syahruddin; Nathaniel Aditya; Jamal Zaini; Ferry Dwi Kurniawan; Sabrina Ermayanti; Noni Novisari Soeroso; Sri Melati Munir; Andreas Infianto; Ana Rima; Ungky Agus Setyawan; Laksmi Wulandari; Haryati Haryati; Ida Ayu Jasminarti; Arif Santoso
Jurnal Respirologi Indonesia Vol 43, No 2 (2023)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v43i2.455

Lung cancer is the leading cause of mortality for all cancer globally and in Indonesia. In Indonesia, lung cancer contributes to 12.6% of death of all cancer, making it the number one cause of cancer death, and 8.6% of all cancer incidence in 2018, behind breast, cervical, and colorectal cancer. The total cases per year are expected to almost double from 30,023 in 2018 to 54,983 cases in 2040. Smoking is among the risk factors for lung cancer, after occupational/environmental risk factors, history of lung fibrosis, and family history of cancer. There was a tendency of younger smokers in Indonesia and increased lung cancer incidence and prevalence in the younger population. The median age of lung cancer in Indonesia was younger than in any country, probably due to the younger age of smoking, early onset of carcinogens, asbestos use, and environmental. Lung cancer screening is a voluntary measure to detect lung cancer in the earliest stage, to find cancer at curable disease before symptoms appear in high-risk individuals. Lung cancer early detection is strategies to find cancer earlier after symptoms appear (cough, hemoptysis, dyspnea, chest pain). Low-dose computerized tomography of the thorax (LDCT) screening has been known to reduce lung cancer mortality compared to a chest x-ray (CXR). This Indonesian Society of Respirology consensus statement was aimed to give recommendations on lung cancer screening and early diagnosis in Indonesia.

Diversity of Fungal Colonization in Respiratory Tract of NaÃ¯ve Lung Cancer and The Emergence of Voriconazole Resistant Aspergillus Jamal Zaini; Abul A'la Al Maududi; Zahrah Annisa; Denny Grecius Siregar; Findra Setianingrum; Mulyati Tugiran; Ridhawati Sjam; Robiatul Adawiyah; Anna Rozaliyani; Sita Andarini; Elisna Syahruddin
HAYATI Journal of Biosciences Vol. 30 No. 6 (2023): November 2023
Publisher : Bogor Agricultural University, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.4308/hjb.30.6.1139-1148

Fungal spores in the air can be inhaled and enter the human respiratory tract. The entry of fungi into the respiratory tract can cause colonization or infection depending on the host immune response. Fungal colonization is the first step into debilitating fungal disease in humans, especially in immunocompromised groups. The increased rate of drug-resistant fungi has been reported in human disease and the environment. This study aims to examine the diversity of fungal colonization in humans and the rate of fungal resistance to voriconazole. This cross-sectional study was done in patients with naÃ¯ve lung cancer who had not been previously treated with any cancer therapy nor given antifungal agent. Induced sputum from 70 subjects was collected and inoculated in the Sabouraud Dextrose Agar medium. Macroscopic and microscopic examinations were performed to identify fungal species. Voriconazole susceptibility tests were done using the disc diffusion method. This study found Candida albicans, Aspergillus niger, Aspergillus fumigatus, and Penicillium sp. among the most common lower respiratory tract colonies. This study also found the colonization of up to 5 species in a single subject. A high rate of voriconazole-resistant Aspergillus sp. was found (42.4%) among 59 isolates tested. Given that these subjects had never taken antifungal agents previously, the high rate of voriconazole resistance might be attributed to the environment, such as community and agriculture. Mitigation of antifungal use in the agricultural sector, fungal diversity in the environment, and clinical study of fungal colonization/ infection in other high-risk groups are needed.

Hematologic Paraneoplastic Syndrome in Newly Diagnosed Patients with Lung Cancer Andika Chandra Putra; Steven Jonathan; Wira Winardi; Elisna Syahruddin
Jurnal Respirasi Vol. 9 No. 1 (2023): January 2023
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v9-I.1.2023.18-29

Introduction: Lung cancer could have signs and symptoms generated by paraneoplastic syndromes. This study aimed to describe and analyze hematologic paraneoplastic syndrome in patients with lung cancer in Indonesia. Methods: This was a cross-sectional analytic study conducted in Persahabatan National Respiratory Referral Hospital, Jakarta, between September 2018 and February 2019, on all newly diagnosed patients with lung cancer whose diagnosis was established and who fulfilled the inclusion and exclusion criteria. Results: The mean age of subjects was 56.7 ± 11.4 years old. Most subjects were male, had normal nutritional status (42.6%), had a smoking history (75%), and had a moderate Brinkman Index (BI) value (52%). The most common type of histology was squamous cell carcinoma (SCC) (39.7%), with advanced stage (83.8%) and performance status <2 (94.1%). Paraneoplastic anemia was 40.4%, associated with poor nutritional status and commonly normocytic normochromic anemia. The proportion of paraneoplastic leukocytosis was 39%, associated with males and smoking history. The proportion of paraneoplastic neutrophilia was 51.5%, and it was related to males, smoking history, and SCC histology type. Paraneoplastic hypereosinophilia and thrombocytosis proportions were 2.9% and 18.4%, respectively. The proportion of paraneoplastic hypercoagulability was 91.2%, which was caused by the elevated D-dimer level. Conclusion: The most common hematologic paraneoplastic syndromes in patients with lung cancer were hypercoagulability, neutrophilia, and anemia. The low hemoglobin (Hb) level of paraneoplastic anemia was associated with low body mass index (BMI). Male and smoking history in lung cancer patients were associated with paraneoplastic leukocytosis and/or neutrophilia.

Indonesian Society of Respirology Position Paper on Lung Cancer Control in Indonesia Andarini, Sita; Santoso, Andintia Aisyah; Arfiansyah, Mochammad Aris; Syahruddin, Elisna; Zaini, Jamal; Putra, Andika Chandra; Kurniawan, Ferry Dwi; Ermayanti, Sabrina; Soeroso, Noni Novisari; Munir, Sri Melati; Infianto, Andreas; Setijadi, Ana Rima; Setyawan, Ungky Agus; Wulandari, Laksmi; Haryati, Haryati; Jasminarti, Ida Ayu; Hidayat, Moulid; Santoso, Arif
Jurnal Respirologi Indonesia Vol 44, No 4 (2024)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v44i4.884

Lung cancer is a major health concern in Indonesia due to its increasing prevalence, late-stage diagnosis, younger population, and high mortality. Addressing this issue requires nationwide implementation of comprehensive lung cancer control, which includes risk reduction and prevention strategies, focusing on tobacco control and air pollution mitigation. Screening with low-dose computed tomography (LDCT) and early detection in symptomatic patients, along with TB screening programs and all non-communicable diseases, is strongly recommended to enhance early case findings, treatment effectiveness, and overall patient outcomes. A multidisciplinary team (MDT) approach is important to ensure accurate diagnosis and comprehensive care. Moreover, the integration of palliative care at the early stages of advanced lung cancer is vital, focusing on symptom management and enhancing the quality of life for patients. While national guidelines are available for the diagnosis and treatment of lung cancer, significant disparities in healthcare access remain across Indonesia. Thus, it is essential to improve universal health coverage and referral systems to guarantee equal access to lung cancer care for patients at all levels through advocacy and ease of access.

Co-Authors Abul A'la Al Maududi Afiani, Dina Ahmad Hudoyo Ahmad Hudoyo AHMAD HUDOYO Aldri Frinaldi Alma Thahir Pulungan Ana Rima Ana Rima Setijadi Ananda, Fannie Rizki Andalucia, Rizka Andarini, Sita Andi Yasmon Andreas Infianto Anna Rozaliyani Annisa Dian Harlivasari Anwar Jusuf Anwar Jusuf Arfiansyah, Mochammad Aris Aria Kekalih Arif Faisal ARIF R HANAFI ARIF R HANAFI, ARIF R Arif Santoso Arif Santoso Ath-Thobari, Jarir AZIZA G ICKSAN AZIZA G ICKSAN, AZIZA G Aziza Icksan Aziza Icksan Buana, Indra Budiman Bela Denny Grecius Siregar Dian Cahyadi Dian Yulianti Duyen, Natalie Erlina Burhan Ermayanti, Sabrina Ermayanti, Sabrina Erni Mudhiati EVLINA SUZANNA, EVLINA Fariz, Nurwidya Feni Fitriani Fera Ibrahim Ferry Dwi Kurniawan Findra Setianingrum Fitri Nurhayati GRACE SHALMONT, GRACE Hanif, Muhammad Alfin Haryati Haryati Haryati Haryati Hasbullah Thabrany Heriawaty Hidajat Heriawaty Hidajat, Heriawaty Hidayat, Moulid Ida Ayu Jasminarti Ida Ayu Jasminarti Dwi Kusumawardani Infianto, Andreas Jasminarti, Ida Ayu Kurniawan, Ferry Dwi Laksmi Wulandari Lia G. Partakusuma Lim, Darren Wan-Teck Lisnawati Lisnawati Melva Louisa Mia Elhidsi Mulatsari, Esti Mulyati Tugiran Nathaniel Aditya Noni Novisari Soeroso Novita Andayani, Novita Nurmadani, Labbaika PRADNYA SRI RAHAYU, PRADNYA SRI Pratama, Avissena Dutha Pratiwi, Suryanti Dwi Putra, Andika Chandra Putra, Muhammad Yusuf Adira Rahmat Hidayat Ramadhaniah, Fariha Rianyta Rianyta Ridhawati Sjam Rita Khairani Robiatul Adawiyah Romi Baginta Santoso, Andintia Aisyah Saputra, Tetra Arya Sarah Fitriani Sayekti, Mutia A. Setiaputra Setiaputra Setyawan, Ungky Agus Shanty R. Kusumawardani Sita Andarini Sita Andarini Sita Andarini Soehardiman, Dicky Solly Aryza Sri Melati Munir Sri Melati Munir Steven Jonathan Tamam Anugrah TAMSIL Tarigan, Setia Putra Taufik Ashar Vivian Soetikno Winnugroho Wiratman, Manfaluthy Hakim, Tiara Aninditha, Aru W. Sudoyo, Joedo Prihartono Wira Winardi Yayi DB Susanto Yopi Simargi Yopi Simargi, Yopi Yuliyanti, Sayekti Yusi Anggriani Zahrah Annisa Zaini, Jamal

Title

Found 28 Documents
Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title Search

Found 28 Documents Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 28 Documents
Search